戻る Agenda
Globalisation of Pharmacovigilance and Impact of COVID-19 Pandemic
Session Chair(s)
Esteban Herrero-Martinez, PhD
Director Regulatory Policy and Intelligence
Novartis Pharmaceuticals UK Limited, United Kingdom
There is a global focus on development of PV legislation and a need to support its development into effective PV systems. In addition, the pandemic has both strained the system and forced innovation. This session will explore some key developments.
Learning Objective : To demonstrate the importance of multi-stakeholder collaboration to facilitate development of effective pharmacovigilance systems worldwide and explain some of the key industry driven initiatives. To interpret what the key COVID-19 pandemic learnings have been to date from for global pharmacovigilance.
Speaker(s)
Introduction
Esteban Herrero-Martinez, PhD
Novartis Pharmaceuticals UK Limited, United Kingdom
Director Regulatory Policy and Intelligence
Effective PV Systems
Willemijn van der Spuij, MSc
Bristol Myers Squibb, Switzerland
Executive Director Europe | International - Patient Safety
Focusing in: Impact of the COVID-19 Pandemic on Global Pharmacovigilance
Pat Harding
Eli Lilly and Company, United Kingdom
Senior Advisor, Medicines Quality Organisation – International,
The importance of global standardisation in covid-19 pharmacovigilance
Rebecca Ellen Chandler, DrMed
Uppsala Monitoring Centre, Sweden
Senior pharmacovigilance expert